These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 30098040)
1. Metabolism of steroids by cytochrome P450 2C9 variants. Uno T; Nakano R; Kitagawa R; Okada M; Kanamaru K; Takenaka S; Uno Y; Imaishi H Biopharm Drug Dispos; 2018 Sep; 39(8):371-377. PubMed ID: 30098040 [TBL] [Abstract][Full Text] [Related]
2. Metabolism of 7-ethoxycoumarin, flavanone and steroids by cytochrome P450 2C9 variants. Uno T; Nakano R; Kanamaru K; Takenaka S; Uno Y; Imaishi H Biopharm Drug Dispos; 2017 Nov; 38(8):486-493. PubMed ID: 28758225 [TBL] [Abstract][Full Text] [Related]
3. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Yamazaki H; Shimada T Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296 [TBL] [Abstract][Full Text] [Related]
4. Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Schwarz D; Kisselev P; Schunck WH; Chernogolov A; Boidol W; Cascorbi I; Roots I Pharmacogenetics; 2000 Aug; 10(6):519-30. PubMed ID: 10975606 [TBL] [Abstract][Full Text] [Related]
5. Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants. Takeji S; Okada M; Hayashi S; Kanamaru K; Uno Y; Imaishi H; Uno T Biopharm Drug Dispos; 2023 Dec; 44(6):420-430. PubMed ID: 37815926 [TBL] [Abstract][Full Text] [Related]
7. Contribution of the human cytochrome P450 2C subfamily to the metabolism of and the interactions with endogenous compounds including steroid hormones. Niwa T; Yasuda S; Yamamoto Y; Murakami M; Ishii R Pharmazie; 2021 Dec; 76(12):611-613. PubMed ID: 34986958 [TBL] [Abstract][Full Text] [Related]
8. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015 [TBL] [Abstract][Full Text] [Related]
9. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164 [TBL] [Abstract][Full Text] [Related]
10. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Lasker JM; Wester MR; Aramsombatdee E; Raucy JL Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596 [TBL] [Abstract][Full Text] [Related]
11. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Yamazaki H; Shimada T Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945 [TBL] [Abstract][Full Text] [Related]
12. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495 [TBL] [Abstract][Full Text] [Related]
13. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. Butler AM; Murray M J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313 [TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Wang L; Bao SH; Pan PP; Xia MM; Chen MC; Liang BQ; Dai DP; Cai JP; Hu GX Drug Dev Ind Pharm; 2015; 41(8):1363-7. PubMed ID: 25144335 [TBL] [Abstract][Full Text] [Related]
15. Down-regulation of rat hepatic microsomal cytochromes P-450 in microvesicular steatosis induced by orotic acid. Su GM; Sefton RM; Murray M J Pharmacol Exp Ther; 1999 Dec; 291(3):953-9. PubMed ID: 10565810 [TBL] [Abstract][Full Text] [Related]
16. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase. Velazquez MNR; Parween S; Udhane SS; Pandey AV Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914 [TBL] [Abstract][Full Text] [Related]
17. Hydrophobic side chain requirements for lauric acid and progesterone hydroxylation at amino acid 113 in cytochrome P450 2C2, a potential determinant of substrate specificity. Straub P; Johnson EF; Kemper B Arch Biochem Biophys; 1993 Nov; 306(2):521-7. PubMed ID: 8215458 [TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of CYP2C11 by diclofenac. Masubuchi Y; Ose A; Horie T Drug Metab Dispos; 2001 Sep; 29(9):1190-5. PubMed ID: 11502726 [TBL] [Abstract][Full Text] [Related]
19. Engineering of CYP106A2 for steroid 9α- and 6β-hydroxylation. Nikolaus J; Nguyen KT; Virus C; Riehm JL; Hutter M; Bernhardt R Steroids; 2017 Apr; 120():41-48. PubMed ID: 28163026 [TBL] [Abstract][Full Text] [Related]
20. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. Gentile DM; Verhoeven CH; Shimada T; Back DJ J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]